» Articles » PMID: 6344747

Viability, Heat Stability and Immunogenicity of Four BCG Vaccines Prepared from Four Different BCG Strains

Overview
Date 1983 Jan 1
PMID 6344747
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Four BCG strains, French 1173-P2, Danish 1331, Japanese 172 and Glaxo-1077, among those most widely used throughout the world for tuberculosis vaccination, were prepared according to the respective conditions in each BCG-production unit. These 16 vaccine preparations were distributed and compared using standardized in vitro and in vivo conditions, based on optical density and bacillary mass/ml. The results presented in this report concern only the 4 freeze-dried BCG strains prepared by the Institut Pasteur BCG unit. It is shown that these 4 preparations differ in their in vitro characteristics such as growth, morphology, heat stability and viability, tested by colony-forming units and the ATP content. In addition, statistically significant differences were observed in biological control tests performed in guinea-pigs and mice when they were immunized with the same concentrations of 4 reconstituted vaccines. For instance, in tests measuring hallmarks of cell-mediated immunity--such as local granuloma formation, spleen index, delayed-type hypersensitivity to tuberculin, and non-specific immunopotentiation to unrelated antigen--a ranking order of relative immunopotency of the four strains was made, giving the following classification in decreasing order: French 1173-P2, Danish 1331, Japanese 172 and Glaxo-1077. Specific acquired resistance after BCG vaccination in mice was obtained with all four vaccines. However, higher protection was observed in mice vaccinated with Glaxo-1077 and French 1173-P2 strains. No obvious correlation existed between the intensity of cellular post-vaccination resistance and the above CMI tests, except those concerning the three-week index of BCG infection measured in the spleen, which correlated with the protection test.

Citing Articles

COVID-19 and Beyond: Exploring Public Health Benefits from Non-Specific Effects of BCG Vaccination.

Koster K, Webb H, Cirillo J Microorganisms. 2021; 9(10).

PMID: 34683441 PMC: 8539044. DOI: 10.3390/microorganisms9102120.


Optimisation of BCG Fermentation and Storage Survival.

Pascoe J, Hendon-Dunn C, Birch C, Williams G, Chambers M, Bacon J Pharmaceutics. 2020; 12(9).

PMID: 32971826 PMC: 7558299. DOI: 10.3390/pharmaceutics12090900.


BCG as a Case Study for Precision Vaccine Development: Lessons From Vaccine Heterogeneity, Trained Immunity, and Immune Ontogeny.

Angelidou A, Diray-Arce J, Conti M, Smolen K, van Haren S, Dowling D Front Microbiol. 2020; 11:332.

PMID: 32218774 PMC: 7078104. DOI: 10.3389/fmicb.2020.00332.


Licensed Bacille Calmette-Guérin (BCG) formulations differ markedly in bacterial viability, RNA content and innate immune activation.

Angelidou A, Conti M, Diray-Arce J, Benn C, Shann F, Netea M Vaccine. 2020; 38(9):2229-2240.

PMID: 32005538 PMC: 7556328. DOI: 10.1016/j.vaccine.2019.11.060.


Improvement of Thermal Stability of BCG Vaccine.

Jahanbakhsh Sefidi F, Kaghazian H, Moradli G, Hassanzadeh S Iran Biomed J. 2017; 21(6):406-10.

PMID: 28605892 PMC: 5572437. DOI: 10.18869/acadpub.ibj.21.6.406.